Advertisement
Table 1 Demographics, clinical data, and procedural observations for the study population and for groups by procedural posture.
| All patients | Supine | Semi-recumbent | p-value* | |
|---|---|---|---|---|
| n | 69 | 33 | 36 | |
| Age | 62 ± 14 | 64 ± 16 | 61 ± 13 | NS |
| Males (%) | 42 (61) | 19 (58) | 23 (64) | NS |
| Smoking status | ||||
| - Current smokers (%) | 15 (22) | 9 (27) | 6 (17) | NS |
| - Ex-smokers (%) | 33 (48) | 16 (49) | 17 (47) | NS |
| - Non-smokers (%) | 21 (30) | 8 (24) | 13 (36) | NS |
| Inpatients (%) | 26 (38) | 11 (33) | 15 (42) | NS |
| Baseline SpO2 | 97.0 ± 2.2 | 96.9 ± 2.4 | 97.1 ± 1.9 | NS |
| Baseline pulse rate (/min) | 77 ± 13 | 76 ± 13 | 77 ± 13 | NS |
| % predicted FEV1 | 70 ± 19 | 67 ± 21 | 74 ± 17 | NS |
| % predicted FVC | 78 ± 17 | 79 ± 19 | 77 ± 14 | NS |
| Oral route (%) | 31 (45) | 15 (45) | 17 (47) | NS |
| Initial phase (min) | 3.7 ± 1.3 | 3.9 ± 1.5 | 3.6 ± 1.1 | NS |
| Cough rate (/min) | 4.8 ± 3.7 | 6.1 ± 4.5 | 3.6 ± 2.3 | 0.007 |
| Sedative use | ||||
| - Midazolam (mg) | 3.5 ± 1.7 | 4.0 ± 2.0 | 3.1 ± 1.2 | 0.029 |
| - Fentanyl (mcg) | 79 ± 30 | 88 ± 28 | 70 ± 29 | 0.011 |
| Nadir SpO2 | 93.4 ± 4.6 | 93.3 ± 4.3 | 93.6 ± 4.9 | NS |
| Fall in SpO2 | 3.6 ± 4.2 | 3.6 ± 3.6 | 3.6 ± 4.7 | NS |
| Peak pulse rate (/min) | 92 ± 16 | 91 ± 17 | 94 ± 15 | NS |
| Rise in pulse rate (/min) | 16 ± 13 | 16 ± 12 | 16 ± 14 | NS |
| Maximal O2 use (L/min) | 3.0 ± 1.8 | 3.0 ± 2.1 | 3.0 ± 1.5 | NS |
| Questionnaire† | ||||
| - Nurse VAS discomfort | 31 ± 26 | 39 ± 28 | 23 ± 21 | 0.01 |
| - Patient VAS recall | 49 ± 35 | 51 ± 35 | 47 ± 36 | NS |
| - Patient VAS discomfort | 24 ± 23 | 22 ± 23 | 27 ± 23 | NS |
| - Patient VAS cough | 33 ± 27 | 40 ± 28 | 28 ± 25 | 0.067 |
| - Patient 1-4 repeat | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.1 ± 0.4 | NS |
